Caris Life Sciences (CAI) Receivables (2024 - 2026)

Caris Life Sciences' Receivables history runs 3 years deep, the most recent figure standing at $94.2 million for Q1 2026.

• In Q1 2026, Receivables changed N/A year-over-year to $94.2 million; the TTM figure through Mar 2026 stood at $94.2 million (changed N/A YoY), while the FY2025 annual figure was $119.3 million, up 28.54% from the prior year.
• Receivables was $94.2 million for Q1 2026 at Caris Life Sciences, down from $119.3 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $119.3 million in Q4 2025 to a low of $36.6 million in Q3 2025.
• Historically, Receivables has averaged $81.0 million across 3 years, with a median of $92.8 million in 2024.
• Biggest YoY gain for Receivables was 28.54% in 2025; the steepest drop was 28.54% in 2025.
• A 3-year view of Receivables shows it stood at $92.8 million in 2024, then increased by 28.54% to $119.3 million in 2025, then retreated by 21.05% to $94.2 million in 2026.
• The last three Receivables figures came in at $94.2 million (Q1 2026), $119.3 million (Q4 2025), and $36.6 million (Q3 2025), per Business Quant data.